PeproMene Bio Highlights Complete Remission in Refractory Cancer Patient with First-in-Class BAFFR-Targeted CAR-T Therapy PMB-CT01

Jan 19, 2024 07:49 CST Updated 07:49

PeproMene Bio

Developer of New Therapies for Cancer and Immune Diseases

▎Edited by the WuXi AppTec content team

PeproMene Bio, Inc. announced today that itsCAR-T Cell Therapy Targeting B Cell Activating Factor Receptor (BAFFR)PMB-CT01 Achieves Positive Results in Phase 1 Clinical Trial for Relapsed/Refractory Acute B Lymphoblastic Leukemia (r/r B-ALL).The first patient in the first cohort achieved complete remission one month after treatment.It is worth mentioning that,The patient had relapsed after prior chemotherapy and blinatumomab treatment, and his disease was CD19- and CD22-negative at the time of relapse, meaning he had very limited treatment options available.。

PMB-CT01 is a potential "first-in-class" BAFFR-targeting autologous CAR-T cell therapy. BAFFR is a member of the tumor necrosis factor (TNF) receptor superfamily and the primary receptor for BAFF, being expressed almost exclusively on B cells.Since BAFFR signaling promotes the proliferation of normal B cells and appears to be essential for B cell survival, it is unlikely that tumor cells can evade immune responses by losing BAFFR antigen. This characteristic makes BAFFR-targeted CAR-T therapy highly promising for treating B-cell malignancies.

BAFFR-Targeted CAR-T Utilizes a Single-Chain Variable Fragment Antibody Against BAFFR and a Second-Generation Signaling Domain Comprising CD3ζ and 4-1BB. Preclinical Studies Have Shown That This CAR-T Cell Therapy Can Eliminate Human Lymphoma and Leukemia Cells In Vitro and In Animal Models. PMB-CT01 Was Developed in the Laboratory of Dr. Larry W. Kwak, Vice President and Deputy Director of the City of Hope Comprehensive Cancer Center and Scientific Founder of PeproMene. PeproMene Has Obtained the Intellectual Property License Related to PMB-CT01 from City of Hope.

In the first month of treatment, the patient only exhibited mild toxicity reactions post-treatment, including Grade 1 cytokine release syndrome (CRS), which resolved without intervention, and there were no signs of immune effector cell-associated neurotoxicity syndrome (ICANS).One month later, the patient not only achieved complete remission but also met the standard of minimal residual disease (MRD) negativity.

At the 2023 American Society of Hematology (ASH) Annual Meeting held in San Diego, PeproMene Bio presented a clinical trial report on PMB-CT01 for the treatment of relapsed/refractory non-Hodgkin lymphoma. All three patients achieved durable complete remission with minimal therapy-related toxicity. The results announced today further supplement this trial.

Everyone is watching

As a CTDMO under WuXi AppTec that focuses on cell and gene therapies, WuXi ATU is committed to accelerating and transforming the development, testing, manufacturing, and commercialization of gene and cell therapies as well as other advanced therapies. WuXi ATU can help global customers bring more innovative therapies to market sooner, benefiting patients. If you have related business needs, please click on the image below to fill in the specific information.

▲If you have any business needs, please long press to scan the QR code above, or click "Read more" at the end of the article to access the business对接 platform and fill in your business needs information.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press to scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

References:

[1] PeproMene Bio announces complete remission achieved in B-ALL patients in PMB-CT01 Phase 1 clinical trial | Successful outcome. Retrieved January 18, 2024, from https://www.prnasia.com/story/434368-1.shtml

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.

Share，PointLike，In view, Focusing on Global Biomedical Health Innovation